Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma

Inclusion Criteria:

• Recurrent ovarian, fallopian tube, or primary peritoneal carcinoma. Histologic orcytologic confirmation of the original primary tumor is required.

• Must have measurable disease which is defined as at least one lesion that can beaccurately measured in at least one dimension. Each lesion must be >20mm when measuredby conventional techniques.

• Must have at least one "target lesion" to be used to assess response.

• Platinum-sensitive tumors, defined as a platinum free interval of at least 6 months,and may have had up to two prior treatment regimens.

• Eastern Cooperative Oncology Group score of 0 or 1

• Life expectancy of 12 weeks or longer

• 18 years of age or older

• Adequate bone marrow, renal, neurologic and liver function

• Normal blood coagulation parameters

Exclusion Criteria:

• Chemotherapy within last 3 weeks

• Current, recent (within 4 weeks), or planned participation in an experimental drugstudy other than a Genentech-sponsored bevacizumab cancer study.

• Known bleeding disorder or coagulopathy, or history of stroke.

• Major surgical procedure, open biopsy, or significant traumatic injury within 28 daysprior to study entry or the anticipation of need for major surgical procedure duringthe course of the study.

• Minor surgical procedures within 14 days of study entry.

• Significant cardiovascular disease, New York Heart Association Grade II or greatercongestive heart failure, serious cardiac arrhythmia requiring medication, a historyof deep vein thrombosis, or Grade II or greater, clinically significant peripheralvascular disease within 1 year of study entry.

• Urine protein:creatinine ration greater than or equal to 1.0

• History or clinical evidence of central nervous system disease

• Patients with other invasive malignancies, with the exception of non-melanoma skincancer, who have evidence of disease within last three years.

• More than 2 prior lines of chemotherapy

• Previous treatment with a VEGF targeted inhibitor or antibody

• Serious non-healing wound, ulcer or bone fracture

• Prior radiation therapy to more than one-third of hematopoietic sites.

• History of abdominal fistulas, gastrointestinal perforation, intra-abdominal abscess,or partial bowel obstruction within 6 months

• Pregnant or lactating